CISPLATIN NEUROTOXICITY - THE RELATIONSHIP BETWEEN DOSAGE, TIME, AND PLATINUM CONCENTRATION IN NEUROLOGIC TISSUES, AND MORPHOLOGICAL EVIDENCE OF TOXICITY

被引:296
作者
GREGG, RW
MOLEPO, JM
MONPETIT, VJA
MIKAEL, NZ
REDMOND, D
GADIA, M
STEWART, DJ
机构
[1] OTTAWA REG CANC CTR, ONTARIO CANC TREATMENT & RES FDN, OTTAWA, ONTARIO, CANADA
[2] UNIV OTTAWA, FAC HLTH SCI, OTTAWA K1N 6N5, ONTARIO, CANADA
关键词
D O I
10.1200/JCO.1992.10.5.795
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To identify the major sites of platinum accumulation within neural tissues after treatment with cisplatin and to determine the relationship between cumulative dosage, time, and the development of histopathological and clinical neurotoxicify. Patients and Methods: Twenty-one patients treated antemortem with cisplatin had neural tissue harvested at autopsy. Neural tissues were assayed for platinum and examined for histopathologic evidence of neurotoxicity. The relationship between histopathologic neurotoxicity and various pharmacologic parameters was analyzed. Results: Tissue platinum levels were found to be highest in the dorsal root ganglia and lowest in tissue protected by the blood-brain barrier. For peripheral nerve, dorsal root, and dorsal root ganglia, a linear relationship was observed between platinum levels and cumulative dose. Platinum levels in neural tissue were not observed to decrease with time. Histopathologic toxicity closely matched an index of exposure to platinum (cumulative dose and log of time). Clinical and histopathologic neurotoxicity was found to occur with higher accumulations of platinum, with the highest levels found in patients with clinical evidence of neurotoxicity. Conclusions: The dorsal root ganglia was the most vulnerable neural structure. This is consistent with the clinical presentation of sensory neuropathy in cisplatin neurotoxicity. Central structures of the spinal cord and brain were protected from platinum accumulation. The increasing histopathologic toxicity, with an index of exposure to platinum, suggests that it is retained indefinitely in an actively neurotoxic form. The pharmacologic parameters examined correlate with the development of and are consistent with the clinical and laboratory features of cisplatin neurotoxicity. © 1992 by American Society of Clinical Oncology.
引用
收藏
页码:795 / 803
页数:9
相关论文
共 54 条
  • [1] PERIPHERAL NEUROPATHY AND OPHTHALMOLOGIC TOXICITY AFTER TREATMENT WITH CIS-DICHLORODIAMINOPLATINUM-II
    BECHER, R
    SCHUTT, P
    OSIEKA, R
    SCHMIDT, CG
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1980, 96 (02) : 219 - 221
  • [2] BOZZINO JM, 1981, CANCER TREAT REP, V65, P351
  • [3] EARLY CLINICAL-STUDIES WITH CIS-DIAMMINE-1,1-CYCLOBUTANE DICARBOXYLATE PLATINUM-II
    CALVERT, AH
    HARLAND, SJ
    NEWELL, DR
    SIDDIK, ZH
    JONES, AC
    MCELWAIN, TJ
    RAJU, S
    WILTSHAW, E
    SMITH, IE
    BAKER, JM
    PECKHAM, MJ
    HARRAP, KR
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (03) : 140 - 147
  • [4] CARBOPLATIN - CURRENT STATUS AND FUTURE-PROSPECTS
    CANETTA, R
    BRAGMAN, K
    SMALDONE, L
    ROZENCWEIG, M
    [J]. CANCER TREATMENT REVIEWS, 1988, 15 : 17 - 32
  • [5] COSTALL B, 1987, British Journal of Pharmacology, V90, p90P
  • [6] COWAN JD, 1980, CANCER TREAT REP, V64, P1119
  • [7] CIS-DIAMMINEDICHLOROPLATINUM, VINBLASTINE, AND BLEOMYCIN COMBINATION CHEMOTHERAPY IN DISSEMINATED TESTICULAR CANCER
    EINHORN, LH
    DONOHUE, J
    [J]. ANNALS OF INTERNAL MEDICINE, 1977, 87 (03) : 293 - 298
  • [8] CURRENT CONCEPTS IN CANCER - ROLE OF CIS-PLATINUM IN SOLID-TUMOR THERAPY
    EINHORN, LH
    WILLIAMS, SD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (06) : 289 - 291
  • [9] VP-16 AND CISPLATIN AS 1ST-LINE THERAPY FOR SMALL-CELL LUNG-CANCER
    EVANS, WK
    SHEPHERD, FA
    FELD, R
    OSOBA, D
    DANG, P
    DEBOER, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (11) : 1471 - 1477
  • [10] FEUN LG, 1984, CANCER, V54, P794, DOI 10.1002/1097-0142(19840901)54:5<794::AID-CNCR2820540503>3.0.CO